I agree that this site is using cookies. You can find further informations here.
X
Galetin, Aleksandra
85  results:
Articles (Online) X
Search for persons X
?
1

Plasma protein binding in special populations: do current P..:

Al-Qassabi, Jokha ; Tan, Shawn ; Galetin, Aleksandra..
Drug Metabolism and Pharmacokinetics.  55 (2024)  - p. 100976 , 2024
Link: https://doi.org/10.1016/..
 
?
2

In silico modeling and simulation of organ‐on‐a‐chip system..:

Milani, Nicoló ; Parrott, Neil ; Galetin, Aleksandra..
CPT: Pharmacometrics & Systems Pharmacology.  13 (2024)  4 - p. 524-543 , 2024
Link: https://doi.org/10.1002/..
 
?
3

Dealing With Variable Drug Exposure Due to Variable Hepatic..:

Rostami‐Hodjegan, Amin ; Al‐Majdoub, Zubida M. ; von Grabowiecki, Yannick...
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
4

Bringing totality-of-evidence into PBPK predictions: fracti..:

Izat, Nihan ; Houston, J. Brian ; Barber, Jill..
Drug Metabolism and Pharmacokinetics.  55 (2024)  - p. 100953 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Facing the Facts of Altered Plasma Protein Binding: Do Curr..:

Al-Qassabi, Jokha ; Tan, Shawn Pei Feng ; Phonboon, Patcharapan...
Journal of Pharmaceutical Sciences.  113 (2024)  6 - p. 1664-1673 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Membrane transporters in drug development and as determinan..:

Galetin, Aleksandra ; Brouwer, Kim L. R. ; Tweedie, Donald...
Nature Reviews Drug Discovery.  23 (2024)  4 - p. 255-280 , 2024
Link: https://doi.org/10.1038/..
 
?
7

Development of 4‐Pyridoxic Acid PBPK Model to Support Bioma..:

Tan, Shawn Pei Feng ; Willemin, Marie‐Emilie ; Snoeys, Jan...
Clinical Pharmacology & Therapeutics.  114 (2023)  6 - p. 1243-1253 , 2023
Link: https://doi.org/10.1002/..
 
?
8

Estimation of FMO3 Ontogeny by Mechanistic Population Pharm..:

Cleary, Yumi ; Kletzl, Heidemarie ; Grimsey, Paul...
Clinical Pharmacokinetics.  62 (2023)  6 - p. 891-904 , 2023
Link: https://doi.org/10.1007/..
 
?
9

Use of In Vivo Imaging and Physiologically-Based Kinetic Mo..:

Melillo, Nicola ; Scotcher, Daniel ; Kenna, J. Gerry...
Pharmaceutics.  15 (2023)  3 - p. 896 , 2023
Link: https://doi.org/10.3390/..
 
?
10

Application of a gut–liver-on-a-chip device and mechanistic..:

Milani, Nicoló ; Parrott, Neil ; Ortiz Franyuti, Daniela...
Lab on a Chip.  22 (2022)  15 - p. 2853-2868 , 2022
Link: https://doi.org/10.1039/..
 
?
11

Effect of Chronic Kidney Disease on the Renal Secretion via..:

Tan, Shawn Pei Feng ; Scotcher, Daniel ; Rostami‐Hodjegan, Amin.
Clinical Pharmacology & Therapeutics.  112 (2022)  3 - p. 643-652 , 2022
Link: https://doi.org/10.1002/..
 
?
12

Correction to: Clinical Investigation on Endogenous Biomark..:

Willemin, Marie-Emilie ; Van Der Made, Thomas K. ; Pijpers, Ils...
Clinical Pharmacokinetics.  61 (2022)  3 - p. 463-463 , 2022
Link: https://doi.org/10.1007/..
 
?
13

Clinical Implications of Altered Drug Transporter Abundance..:

Chu, Xiaoyan ; Prasad, Bhagwat ; Neuhoff, Sibylle...
Clinical Pharmacology & Therapeutics.  112 (2022)  3 - p. 501-526 , 2022
Link: https://doi.org/10.1002/..
 
?
14

Exploration and application of a liver-on-a-chip device in ..:

Docci, Luca ; Milani, Nicolò ; Ramp, Thomas...
Lab on a Chip.  22 (2022)  6 - p. 1187-1205 , 2022
Link: https://doi.org/10.1039/..
 
?
15

Coproporphyrin I as an Endogenous Biomarker to Detect Reduc..:

Takita, Hiroyuki ; Scotcher, Daniel ; Chu, Xiaoyan...
Clinical Pharmacology & Therapeutics.  112 (2022)  3 - p. 615-626 , 2022
Link: https://doi.org/10.1002/..
 
1-15